Blue Earth Diagnostics is highlighting clinical results for its Posluma (flotufolastat F-18) PET radiotracer that will be presented at the upcoming American Society for Radiation Oncology (ASTRO) annual meeting in San Diego.
Posulma is indicated for prostate-specific membrane antigen (PSMA)-PET imaging in men with prostate cancer with suspected metastasis. At the meeting, researchers will present further data from phase III trials. In addition, Blue Earth will host an industry-expert theater event titled, "Posluma: Precision PET Imaging that is Truly Revealing."
